Merck CEO Rob Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' Meanwhile, in the U.S., the company’s pneumococcal conjugate vaccine Capvaxive recently scored a key ...

That shot protects against 21 types of the bacteria that cause pneumococcal disease, including eight not covered by other vaccines. Merck has said those eight account for more than one-quarter of ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

Vaccination with CAPVAXIVE may not protect all vaccine recipients. CAPVAXIVE is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of ...

It’s estimated that over 150,000 adults are hospitalized from pneumococcal pneumonia each year in the U.S. Merck has been at the forefront of pneumococcal disease prevention through vaccination ...

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. But Merck's vaccine that ...